Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancer

15 Aug 2025

Abstract excerpt

Tumor gene alterations can serve as predictive biomarkers for therapy response. The nucleotide excision repair (NER) helicase ERCC2 carries heterozygous missense mutations in approximately 10% of bladder tumors, and these may predict sensitivity to cisplatin treatment. To explore the clinical actionability of ERCC2 mutations, we assembled a multinational cohort of 2,012 individuals with bladder cancer and applied...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Cancer Genomics and Diagnostics
Share to DNA Repair Mechanisms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40829180
DOI: 10.1172/jci186688

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitative functional profiling of ERCC2 mutations deciphers cisplatin sensitivity in bladder cancerPMID 40829180Read ↗

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerSemantic proximity Read ↗

ERCC2 mutations alter the genomic distribution pattern of somatic mutations and are independently prognostic in bladder cancer.Semantic proximity Read ↗

Identification of an <i>ERCC2</i> mutation associated mutational signature of nucleotide excision repair deficiency in targeted panel sequencing dataSemantic proximity Read ↗

Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder CancerSemantic proximity Read ↗

Doctors revise Declaration of HelsinkiSemantic proximity Read ↗

Saturation genome editing of 11 codons and exon 13 of BRCA2 coupled with chemotherapeutic drug response accurately determines pathogenicity of variants.Semantic proximity Read ↗

Bioinformatics analysis of ERCC family in pan-cancer and ERCC2 in bladder cancer.Semantic proximity Read ↗

Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.Semantic proximity Read ↗

Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.Semantic proximity Read ↗

Prioritisation of oncology therapeutic targets using CRISPR-Cas9 screeningSemantic proximity Read ↗

XPA tumor variants lead to defects in NER that sensitize cells to cisplatinSemantic proximity Read ↗

Massively parallel assessment of human variants with base editor screens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.